...
首页> 外文期刊>Vlaams Diergeneeskundig Tijdschrift >Primary glaucoma in the dog: a review of the current therapies and the research into future possibilities Part I: medical therapy
【24h】

Primary glaucoma in the dog: a review of the current therapies and the research into future possibilities Part I: medical therapy

机译:狗的主要青光眼:对当前疗法的审查和对未来可能性的研究第I:医疗治疗

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Primary glaucoma is an important and leading cause of incurable blindness and is defined as a progressive optic neuropathy. It is a bilateral, genetic disease where various pathogenic mechanisms are likely to be involved. Certain breeds are more predisposed and gender also plays an important role. Primary glaucomas are divided into two subcategories, according to the appearance of the irido-corneal angle. An important risk factor is an increased eye pressure, and therefore, IOP-lowering (intraocular pressure) treatments remain the gold standard. Currently, the management is aimed at permanent control of the condition with the ultimate goal of a comfortable patient and ideally, an eye capable of seeing. Although medical therapy remains the predominant treatment option and can be used alone, surgery is often necessary to improve intraocular pressure control by reducing the production of aqueous humor and/or increasing its outflow.
机译:原发性青光眼是可治愈的失明的重要和主要原因,被定义为渐进视神经病变。 它是一种双侧,遗传疾病,可能涉及各种致病机制。 某些品种更加倾向于,性别也发挥着重要作用。 根据IRIDO-角膜角度的外观,原发性肺细胞分为两个子类别。 一个重要的风险因素是眼压增加,因此,降低IOP(眼内压)处理仍然是金标准。 目前,管理层旨在永久地控制舒适患者的最终目标,理想情况下是能够看到的眼睛。 虽然医疗疗法仍然是主要的治疗选择,并且可以单独使用,但手术通常需要通过减少水性幽默和/或增加其流出来改善眼内压力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号